Cutis Laxa
Elastic Tissue
Tropoelastin
Pyrroline Carboxylate Reductases
Extracellular Matrix Proteins
Mucinoses
Congenital Disorders of Glycosylation
Frameshift Mutation
Skin
Menkes Kinky Hair Syndrome
Ornithine-Oxo-Acid Transaminase
Psychosocial implications of blepharoptosis and dermatochalasis. (1/63)
PURPOSE: To investigate, for the first time, the psychosocial implications of blepharoptosis and dermatochalasis. METHODS: Two hundred ten individuals rated whole-face photographs of a series of patients on the basis of 11 different personal characteristics: intelligence, throat, friendliness, health, trustworthiness, hard work, mental illness, financial success, attractiveness, alcoholism, and happiness. Preoperative and postoperative photographs of both male and female patients with bilateral blepharoptosis and/or dermatochalasis were used. The paired t test was used to compare preoperative and postoperative ratings on the 11 characteristics. RESULTS: The preoperative photographs were rated more negatively than the postoperative photographs (P < .01-P < .001) on all 11 characteristics for both male and female patients by the 210 study subjects. CONCLUSIONS: Members of society seem to view individuals with blepharoptosis and dermatochalasis negatively. These psychosocial attitudes may lead to unjust bias toward affected patients, and surgical correction likely provides benefits beyond improved visual function. (+info)Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. (2/63)
Hereditary cutis laxa comprises a heterogeneous group of connective tissue disorders characterized by loose skin and variable systemic involvement. Autosomal dominant and recessive as well as X-linked forms have been described. Some dominant forms are caused by mutations in the elastine gene (ELN). The X-linked form is now classified in the group of copper transport diseases. The genetic defect underlying the autosomal recessive (AR) forms of cutis laxa is not known. The phenotypic abnormalities recently observed in a fibulin-5 knockout mouse model are reminiscent of human AR cutis laxa type I. Both share cutis laxa, lung emphysema and arterial involvement. Molecular study of the fibulin-5 (FBLN5) gene in a large consanguineous Turkish family with four patients affected by AR cutis laxa type I demonstrated the presence of a homozygous missense mutation (T998C) in the FBLN5 gene resulting in a serine-to-proline (S227P) substitution in the fourth calcium-binding epidermal growth factor-like domain of fibulin-5 protein. This amino acid substitution is predicted to have important structural and functional consequences for normal elastogenesis. As such, we provide evidence that a genetic defect in fibulin-5 (FBLN5, also known as EVEC or DANCE) is responsible for a recessive form of cutis laxa in humans. (+info)Genetic heterogeneity of cutis laxa: a heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. (3/63)
Inherited cutis laxa is a connective tissue disorder characterized by loose skin and variable internal organ involvement, resulting from paucity of elastic fibers. Elsewhere, frameshift mutations in the elastin gene have been reported in three families with autosomal dominant inheritance, and a family with autosomal recessive cutis laxa was recently reported to have a homozygous missense mutation in the fibulin-5 gene. In the present study, we analyzed the gene expression of elastin and fibulins 1-5 in fibroblasts from five patients with cutis laxa. One patient was found to express both normal (2.2 kb) and mutant (2.7 kb) fibulin-5 mRNA transcripts. The larger transcript contains an internal duplication of 483 nucleotides, which resulted in the synthesis and secretion of a mutant fibulin-5 protein with four additional tandem calcium-binding epidermal growth factor-like motifs. The mutation arose from a 22-kb tandem gene duplication, encompassing the sequence from intron 4 to exon 9. No fibulin-5 or elastin mutations were detected in the other patients. The results demonstrate that a heterozygous mutation in fibulin-5 can cause cutis laxa and also suggest that fibulin-5 and elastin gene mutations are not the exclusive cause of the disease. (+info)Congenital cutis laxa syndrome: type II autosomal recessive inheritance. (4/63)
Cutis laxa is a term that refers to markedly loose skin that is not hyperelastic. It is regarded as a genetically heterogeneous group of diseases and is presently divided into five types. We report a male patient with type II autosomal recessive disease. The patient was the third child of first-cousin consanguineous, healthy parents. His two siblings died a few hours after birth. One of the siblings also had similar features and wrinkled skin. Our case had markedly loose and wrinkled skin especially over the dorsum of the hands and feet, and on the face and abdomen, dolichocephaly, hypertelorism, blepharochalasis, long filtrum, pectus excavatus, large fontanelles, prominent low-set ears and umbilical hernia. These findings and skin biopsy were consistent with cutis laxa syndrome. In addition to these findings, consanguinity, atypical facies, large fontanelles and umbilical hernia were typical manifestations of type II autosomal recessive cutis laxa. (+info)Defective protein glycosylation in patients with cutis laxa syndrome. (5/63)
Congenital cutis laxa is a genetically heterogeneous condition presenting with loose and redundant skin folds, decreased elasticity of the skin, connective tissue involvement and a highly variable spectrum of associated features. The most common forms are inherited in an autosomal recessive or dominant fashion. Fibulin 5 and elastin mutations were detected in a limited number of patients, but in most cases the etiology is not known. Based on a previous observation of an abnormal transferrin isoelectric focusing pattern in a patient with cutis laxa indicating an N-glycosylation defect, we performed a screening for disorders of protein glycosylation in unrelated children with cutis laxa syndrome, including a recently developed test for defective O-glycosylation. Here, we describe five patients from consanguineous marriages with a cutis laxa syndrome with skeletal and joint involvement, developmental delay and neurological findings. Three of these five children have an inborn error of glycan biosynthesis affecting the synthesis of both N- and O-linked glycans. Two patients had normal glycosylation patterns. All known causes of secondary glycosylation disorders were excluded in the children. No mutations were found in the FBLN5 gene. In conclusion, we have identified a new combined glycosylation defect with a distinct clinical phenotype. Our results suggest that a combined defect of glycosylation might be a causative factor in congenital cutis laxa. This is the first report where abnormal N- and O-linked glycosylation is implicated in the etiology of cutis laxa syndrome. (+info)Autosomal dominant cutis laxa with severe lung disease: synthesis and matrix deposition of mutant tropoelastin. (6/63)
Cutis laxa (CL) is a heterogeneous group of genetic and acquired disorders with at least two autosomal dominant forms caused by mutations in the elastin and fibulin-5 genes, respectively. To define the molecular basis of CL in patients negative for point mutations in the elastin gene, metabolic labeling and immunoprecipitation experiments were used to study the synthesis of elastin in dermal fibroblasts. In addition to the normal 68 kDa tropoelastin (TE) protein, an abnormal, 120 kDa polypeptide was detected in the proband and her affected daughter in a CL family characterized by hernias and unusually severe and early-onset pulmonary disease including bronchiectasis and pulmonary emphysema. Mutational and gene expression studies established that affected individuals in this family carried a partial tandem duplication in the elastin locus. Immunoprecipitation experiments showed that the mutant TE was partially secreted and partially retained intracellularly. A polyclonal antibody raised against a unique peptide in the mutant TE molecule showed both intracellular and matrix staining. We conclude that elastin mutations can cause CL associated with a severe pulmonary phenotype. Synthesis of abnormal TE may interfere with elastic fiber function through a dominant-negative or a gain of function mechanism. (+info)A combined defect in the biosynthesis of N- and O-glycans in patients with cutis laxa and neurological involvement: the biochemical characteristics. (7/63)
Based on our preliminary observation of abnormal glycosylation in a cutis laxa patient, nine cutis laxa patients were analyzed for congenital defects of glycosylation (CDG). Isoelectric focusing of plasma transferrin and apolipoproteinC-III showed that three out of nine patients had a defect in the biosynthesis of N-glycans and core 1 mucin type O-glycans, respectively. Mass spectrometric N-glycan analyses revealed a relative increase of glycans lacking sialic acid and glycans lacking sialic acid and galactose residues. Mutation analysis of the fibulin-5 gene (FBLN5), which has been reported in cases of autosomal recessive cutis laxa, revealed no mutations in the patients' DNA. Evidence is presented that extracellular matrix (ECM) proteins of skin are likely to be highly glycosylated with N- and/or mucin type O-glycans by using algorithms for predicting glycosylation. The conclusions in this study were that the clinical phenotype of autosomal recessive cutis laxa seen in three patients is not caused by mutations in the FBLN5 gene. Our findings define a novel form of CDG with cutis laxa and neurological involvement due to a defect in the sialylation and/or galactosylation of N- and O-glycans. Improper glycosylation of ECM proteins of skin may form the pathophysiological basis for the cutis laxa phenotype. (+info)Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene. (8/63)
BACKGROUND: Cutis laxa is an acquired or inherited condition characterized by redundant, pendulous and inelastic skin. Autosomal dominant cutis laxa has been described as a benign disease with minor systemic involvement. OBJECTIVE: To report a family with autosomal dominant cutis laxa and a young girl with sporadic cutis laxa, both with variable expression of an aortic aneurysmal phenotype ranging from mild dilatation to severe aneurysm or aortic rupture. METHODS AND RESULTS: Histological evaluation of aortic aneurysmal specimens indicated classical hallmarks of medial degeneration, paucity of elastic fibres, and an absence of inflammatory or atherosclerotic lesions. Electron microscopy showed extracellular elastin deposits lacking microfibrillar elements. Direct sequencing of genomic amplimers detected defects in exon 30 of the elastin gene in affected individuals, but did not in 121 normal controls. The expression of mutant elastin mRNA forms was demonstrated by reverse transcriptase polymerase chain reaction analysis of cutis laxa fibroblasts. These mRNAs coded for multiple mutant tropoelastins, including C-terminally truncated and extended forms as well as for molecules lacking the constitutive exon 30. CONCLUSIONS: ELN mutations may cause severe aortic disease in patients with cutis laxa. Thus regular cardiac monitoring is necessary in this disease to avert fatal aortic rupture. (+info)There are several types of cutis laxa, including:
1. Oculocutaneous type: This is the most common form of the disorder, and it is characterized by wrinkled skin, loose folds, and skin fragility. People with this type may also have vision loss, cataracts, or other eye problems.
2. Dermato-skeletal type: This type is characterized by loose skin and joint hypermobility, as well as skeletal abnormalities such as short stature, bowed legs, or ribcage deformities.
3. Neurological type: This type is characterized by developmental delay, intellectual disability, and seizures. People with this type may also have other neurological symptoms such as weakness or paralysis of certain muscle groups.
4. Cardiac type: This type is characterized by heart defects, such as ventricular septal defect or atrial septal defect.
There is no cure for cutis laxa, and treatment is focused on managing the symptoms. This may include surgery to correct skin and joint deformities, physical therapy to improve muscle strength and flexibility, and other supportive measures such as glasses or contact lenses to correct vision problems. Early diagnosis and intervention are important to help manage the condition and improve quality of life for individuals with cutis laxa.
The prognosis for individuals with cutis laxa varies depending on the type and severity of the disorder. Some people with mild forms of the condition may lead relatively normal lives, while others with more severe forms may have significant challenges and may require ongoing medical care and support. With appropriate management, many people with cutis laxa can lead fulfilling lives, but it is important to be aware of the potential complications and to seek medical attention if symptoms worsen or new symptoms develop.
Examples of inborn errors of carbohydrate metabolism include:
1. Phosphofructokinase (PFK) deficiency: This is a rare genetic disorder that affects the body's ability to break down glucose-6-phosphate, a type of sugar. Symptoms can include seizures, developmental delays, and metabolic acidosis.
2. Galactosemia: This is a group of genetic disorders that affect the body's ability to process galactose, a type of sugar found in milk and other dairy products. Untreated, galactosemia can lead to serious health problems, including liver disease, kidney damage, and cognitive impairment.
3. Glycogen storage disease type II (GSDII): This is a rare genetic disorder that affects the body's ability to store and use glycogen, a complex carbohydrate found in the liver and muscles. Symptoms can include low blood sugar, fatigue, and muscle weakness.
4. Pompe disease: This is a rare genetic disorder that affects the body's ability to break down glycogen. Symptoms can include muscle weakness, breathing problems, and heart problems.
5. Mucopolysaccharidoses (MPS): These are a group of genetic disorders that affect the body's ability to break down sugar molecules. Symptoms can include joint stiffness, developmental delays, and heart problems.
Inborn errors of carbohydrate metabolism can be diagnosed through blood tests, urine tests, and other diagnostic procedures. Treatment depends on the specific disorder and may involve a combination of dietary changes, medication, and other therapies.
The different types of mucinoses include:
1. Mucinous cystic neoplasms: These are benign tumors that arise from the excessive growth of mucin-secreting cells in the pancreas, liver, or other organs.
2. Mucinous adenoma: This is a type of benign tumor that originates in the colon and is characterized by the accumulation of mucin in the glandular tissue.
3. Mucinosis fungoides: This is a rare form of cutaneous lymphoma that involves the skin and mucous membranes.
4. Mucoepidermoid carcinoma: This is a type of cancer that arises from the glandular tissue of the salivary glands, lacrimal gland, or sweat glands.
5. Mucinous carcinoma: This is a type of cancer that originates in the breast and is characterized by the accumulation of mucin in the tumor cells.
The symptoms of mucinoses can vary depending on the specific type and location of the disease, but may include:
* Lumps or masses in the affected organ or tissue
* Pain or discomfort in the abdomen or other areas
* Difficulty swallowing or breathing (in cases where the mucinoses affect the throat or airways)
* Skin rashes or lesions (in cases of mucinosis fungoides)
* Weight loss and fatigue
The diagnosis of mucinoses is based on a combination of clinical findings, laboratory tests, and imaging studies. Treatment options vary depending on the specific type and location of the disease, but may include surgery, radiation therapy, chemotherapy, or a combination of these.
Prognosis for mucinoses varies depending on the specific type and location of the disease, as well as the stage at which it is diagnosed. In general, early detection and treatment improve prognosis, while advanced stages of the disease are associated with poorer outcomes.
CDGs are caused by mutations in genes that code for enzymes involved in glycosylation, a process that adds sugars to proteins and lipids to form glycoproteins and glycolipids. These molecules play important roles in cell signaling, protein folding, and the immune response. Without proper glycosylation, these molecules cannot function properly, leading to a wide range of symptoms and complications.
Symptoms of CDGs can vary depending on the specific disorder and the organs affected. Common symptoms include developmental delays, intellectual disability, seizures, poor muscle tone, and liver problems. Some children with CDGs may also experience failure to thrive, diarrhea, and vomiting.
There is currently no cure for CDGs, but various treatments are available to manage the symptoms and prevent complications. These may include enzyme replacement therapy, nutritional supplements, and medications to control seizures and other symptoms. In some cases, a bone marrow transplant may be necessary to replace the defective cells with healthy ones.
The diagnosis of CDG is based on a combination of clinical symptoms, laboratory tests, and genetic analysis. Newborn screening is increasingly being used to identify CDGs in infants, allowing for early intervention and treatment.
Overall, congenital disorders of glycosylation are rare and complex conditions that require specialized care and management. With advances in medical technology and research, there is hope for improved treatments and outcomes for individuals with CDGs.
Examples of syndromes include:
1. Down syndrome: A genetic disorder caused by an extra copy of chromosome 21 that affects intellectual and physical development.
2. Turner syndrome: A genetic disorder caused by a missing or partially deleted X chromosome that affects physical growth and development in females.
3. Marfan syndrome: A genetic disorder affecting the body's connective tissue, causing tall stature, long limbs, and cardiovascular problems.
4. Alzheimer's disease: A neurodegenerative disorder characterized by memory loss, confusion, and changes in personality and behavior.
5. Parkinson's disease: A neurological disorder characterized by tremors, rigidity, and difficulty with movement.
6. Klinefelter syndrome: A genetic disorder caused by an extra X chromosome in males, leading to infertility and other physical characteristics.
7. Williams syndrome: A rare genetic disorder caused by a deletion of genetic material on chromosome 7, characterized by cardiovascular problems, developmental delays, and a distinctive facial appearance.
8. Fragile X syndrome: The most common form of inherited intellectual disability, caused by an expansion of a specific gene on the X chromosome.
9. Prader-Willi syndrome: A genetic disorder caused by a defect in the hypothalamus, leading to problems with appetite regulation and obesity.
10. Sjogren's syndrome: An autoimmune disorder that affects the glands that produce tears and saliva, causing dry eyes and mouth.
Syndromes can be diagnosed through a combination of physical examination, medical history, laboratory tests, and imaging studies. Treatment for a syndrome depends on the underlying cause and the specific symptoms and signs presented by the patient.
The main symptoms of Menkes syndrome are:
1. Steel-gray or kinky hair, which starts to appear within the first few months of life.
2. Failure to thrive, poor muscle tone, and low birth weight.
3. Developmental delays and intellectual disability.
4. Seizures and poor coordination.
5. Poor immune function and recurrent infections.
6. Gradual loss of vision and hearing.
7. Osteoporosis and fragile bones.
8. Increased risk of liver disease, including cirrhosis and portal hypertension.
The diagnosis of Menkes syndrome is based on a combination of clinical findings, laboratory tests, and genetic analysis. Treatment is focused on managing the symptoms and preventing complications, and may include copper supplements, anticonvulsants, and other medications.
The prognosis for Menkes syndrome is poor, with most individuals dying in childhood or adolescence due to complications such as liver disease, infections, or seizures. However, some individuals may live into their 20s or 30s with appropriate management and care.
Cutis laxa
List of OMIM disorder codes
SCARF syndrome
Dermatochalasis
Wrinkly skin syndrome
De Barsy syndrome
Familial Amyloidosis, Finnish Type
Lattice corneal dystrophy
Lysyl oxidase
Xenopus
Bruno Reversade
PYCR1
Ehlers-Danlos syndromes
EFEMP2
Transaldolase deficiency
Elastin
ATP6V0A2
Congenital disorder of glycosylation
FBLN5
Gamma-glutamyl carboxylase
Laminin, beta 1
Extracellular matrix
Gerodermia osteodysplastica
Elastic fiber
Aldehyde dehydrogenase 18 family, member A1
Occipital horn syndrome
Menkes disease
Patterson syndrome
PLAID syndrome
Lenz-Majewski syndrome
List of diseases (C)
List of skin conditions
Latin obscenity
List of MeSH codes (C16)
Ardalan-Shoja-Kiuru syndrome
Sexuality in ancient Rome
Cutis laxa - About the Disease - Genetic and Rare Diseases Information Center
Cutis laxa: MedlinePlus Genetics
Cutis laxa: MedlinePlus Genetics
ATP6V0A2-Related Cutis Laxa - PubMed
ATP6V0A2-Related Cutis Laxa - GeneReviews® - NCBI Bookshelf
Canal JDP - CUTIS LAXA INTERNATIONALE
Bi-allelic premature truncating variants in LTBP1 cause cutis laxa syndrome. | Am J Hum Genet;108(6): 1095-1114, 2021 06 03. ...
AUTOSOMAL DOMINANT AND RECESSIVE CUTIS LAXA , NEXT-GENERATION SEQUENCING (NGS) 13 GENES - RefLab Genetics
Additional findings of tibial dysplasia in a male with orofaciodigital syndrome type XVI | Human Genome Variation
Genes
WikiGenes
PGT-M conditions | HFEA
Biomarkers Search
Keipert syndrome - Ontology Browser - Rat Genome Database
AMERICAN JOURNAL OF HUMAN GENETICS
IndexCat
De Barsy syndrome
Congenital Clouding of the Cornea Clinical Presentation: History, Physical, Causes
Increasing amount of amyloid are associated with the severity of clinical features in hereditary gelsolin (AGel) amyloidosis<...
MeSH Browser
Minerva Respiratory Medicine 2023 March;62(1) - Minerva Medica - Journals
Finnish gelsolin amyloidosis causes significant disease burden but does not affect survival: FIN-GAR phase II study | Orphanet...
FDA Safety Labeling Changes: Lupron, Tikosyn, Cuprimine
DailyMed - PENICILLAMINE capsule
RFA-AR-18-005: Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (SBIR) (R43)
Orphanet: Search a disease
LTBP4
- Early...
DeCS
Autosomal dominant4
- In general, the autosomal recessive forms of cutis laxa tend to be more severe than the autosomal dominant forms, although some people with autosomal dominant cutis laxa are severely affected. (medlineplus.gov)
- Autosomal dominant cutis laxa (ADCL), the most common form of the disorder, is primarily caused by variants in the ELN gene. (medlineplus.gov)
- Many of the genes associated with autosomal dominant and autosomal recessive forms of cutis laxa are involved in the formation and function of elastic fibers, which are slender bundles of proteins that provide strength and flexibility to connective tissue throughout the body. (medlineplus.gov)
- Woollons A, Darley CR, Lee PJ, Brenton DP, Sonksen PH, Black MM. Cutis verticis gyrata of the scalp in a patient with autosomal dominant insulin resistance syndrome. (medscape.com)
Connective tissue4
- Cutis laxa is a disorder of connective tissue, which is the tissue that provides structure and strength to the muscles, joints, organs, and skin. (medlineplus.gov)
- Cutis laxa can also affect connective tissue in other parts of the body, including the heart, blood vessels, intestines, and lungs. (medlineplus.gov)
- These defects in connective tissue underlie the major features of cutis laxa. (medlineplus.gov)
- Affected individuals present with connective tissue features ( cutis laxa and inguinal hernia ), craniofacial dysmorphology, variable heart defects, and prominent skeletal features ( craniosynostosis , short stature, brachydactyly , and syndactyly ). (bvsalud.org)
Syndrome7
- The X-linked form of cutis laxa is often called occipital horn syndrome. (medlineplus.gov)
- Other rare conditions, including arterial tortuosity syndrome , geroderma osteodysplastica, and RIN2 syndrome, are sometimes classified as cutis laxa-related conditions, because affected individuals can have loose, sagging skin. (medlineplus.gov)
- Bi-allelic premature truncating variants in LTBP1 cause cutis laxa syndrome. (bvsalud.org)
- De Barsy syndrome is a rare, autosomal recessive disorder of cutis laxa (loose skin). (logicalimages.com)
- Consider the diagnosis of Turner syndrome in female infants with cutis verticis gyrata with or without peripheral lymphedema. (medscape.com)
- Is cutis verticis Gyrata-Intellectual Disability syndrome an underdiagnosed condition? (medscape.com)
- Cutis verticis gyrata in a patient with hyper-IgE syndrome. (medscape.com)
Congenital1
- Although there are no controlled studies of penicillamine use in pregnant women, characteristic congenital cutis laxa and associated birth defects have been reported in infants whose mothers used the drug during pregnancy. (medscape.com)
Infancy1
- While signs and symptoms of inherited cutis laxa are often noticeable in infancy or childhood, acquired cutis laxa typically appears later in life. (medlineplus.gov)
Emphysema1
- During childhood, some people with cutis laxa develop a life-long lung disease called emphysema, which can make it difficult to breathe. (medlineplus.gov)
Genetic1
- Cutis laxa is usually a genetic disease, but acquired cases have been reported. (bvsalud.org)
Genes3
- Cutis laxa can be caused by variants (also known as mutations) in several genes. (medlineplus.gov)
- Other proteins involved in cutis laxa that have critical roles in the assembly of elastic fibers are produced from the EFEMP2 , FBLN5 , LTBP4 , and ATP6V0A2 genes. (medlineplus.gov)
- Two other genes involved in cutis laxa, ALDH18A1 and PYCR1 , provide instructions for making proteins that have important roles in cells. (medlineplus.gov)
Disorder1
- Cutis laxa is a rare disorder. (medlineplus.gov)
Variants1
- Autosomal recessive cutis laxa (ARCL) can be caused by variants in the FBLN5 , EFEMP2 , LTBP4 , ATP6V0A2 , PYCR1 , or ALDH18A1 gene. (medlineplus.gov)
Acute1
- Passarini B, Neri I, Patrizi A, Masina M. Cutis verticis gyrata secondary to acute monoblastic leukemia. (medscape.com)
Intellectual disability1
- In addition to the features described above, people with autosomal recessive cutis laxa can have delayed development, intellectual disability, seizures, problems with movement, or eye or bone abnormalities. (medlineplus.gov)
Nasal1
- Harish V, Clarke F. Isolated cutis verticis gyrata of the glabella and nasal bridge: a case report and review of the literature. (medscape.com)
Term1
- The term "cutis laxa" is Latin for loose or lax skin, and this condition is characterized by skin that is sagging and not stretchy (inelastic). (medlineplus.gov)
Form of cutis laxa2
- The X-linked form of cutis laxa is often called occipital horn syndrome. (medlineplus.gov)
- Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. (medscape.com)
Symptoms of cutis2
- Depending on which organs and tissues are affected, the signs and symptoms of cutis laxa can range from mild to life-threatening. (medlineplus.gov)
- When Do Symptoms of Cutis laxa Begin? (nih.gov)
Abnormalities2
- In addition to the features described above, people with autosomal recessive cutis laxa can have delayed development, intellectual disability, seizures, problems with movement, or eye or bone abnormalities. (medlineplus.gov)
- Defects in this gene may be a cause of cutis laxa and severe pulmonary, gastrointestinal, and urinary abnormalities. (nih.gov)
Elastin2
- Graul-Neumann LM, Hausser I, Essayie M, Rauch A, Kraus C. Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene. (medscape.com)
- Acquired Localized Cutis Laxa due to Increased Elastin Turnover. (medscape.com)
Connective5
- Cutis laxa is a disorder of connective tissue, which is the tissue that provides structure and strength to the muscles, joints, organs, and skin. (medlineplus.gov)
- Cutis laxa can also affect connective tissue in other parts of the body, including the heart, blood vessels, intestines, and lungs. (medlineplus.gov)
- Many of the genes associated with autosomal dominant and autosomal recessive forms of cutis laxa are involved in the formation and function of elastic fibers, which are slender bundles of proteins that provide strength and flexibility to connective tissue throughout the body. (medlineplus.gov)
- These defects in connective tissue underlie the major features of cutis laxa. (medlineplus.gov)
- Cutis laxa is a connective tissue disorder characterized by skin that is sagging and not stretchy. (nih.gov)
Genetic Disease1
- Cutis laxa is usually a genetic disease, but acquired cases have been reported. (bvsalud.org)
FBLN53
- Autosomal recessive cutis laxa (ARCL) can be caused by variants in the FBLN5 , EFEMP2 , LTBP4 , ATP6V0A2 , PYCR1 , or ALDH18A1 gene. (medlineplus.gov)
- Other proteins involved in cutis laxa that have critical roles in the assembly of elastic fibers are produced from the EFEMP2 , FBLN5 , LTBP4 , and ATP6V0A2 genes. (medlineplus.gov)
- FBLN5-Related Cutis Laxa. (medscape.com)
Mutation1
- Homozygous missense mutation in fibulin-5 in an Iranian autosomal recessive cutis laxa pedigree and associated haplotype. (nih.gov)
Defects1
- In inherited cutis laxa an abnormal synthesis of extracellular matrix proteins occurs due to genetic defects coding for diverse extracellular matrix components. (nih.gov)
Type2
- Kumar P, Savant SS, Das A. Generalized acquired cutis laxa type 1: a case report and brief review of literature. (medscape.com)
- Cutis laxa of the autosomal recessive type in a consanguineous family. (nih.gov)
Summary1
- This summary primarily describes inherited forms of cutis laxa. (medlineplus.gov)
Conditions1
- In some of these metabolic conditions the pathomechanism of cutis laxa remains unknown. (nih.gov)
Review1
- Vajdi T, Lee WW, Paravar T. Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine. (medscape.com)